Melanocytic naevi and melanoma in survivors of childhood cancer.
There is evidence from previous studies of small numbers of children who received cytotoxic therapy for cancer, that they may develop increased numbers of melanocytic naevi (moles), the strongest known risk factors for melanoma. Our aim was to investigate a large number of survivors of childhood cancer in order to test the hypothesis that they have more melanocytic naevi than matched controls. Total-body naevus counts were obtained from 263 oncology patients ascertained in paediatric oncology departments in Queensland, Australia, and from 263 hospital controls matched for age and sex. Additional information was gathered from children's parents about concurrent factors influencing naevus development such as type of complexion and history of sun exposure. Matched analyses, both crude and adjusted for possible confounding factors, revealed no significant difference in overall density of naevi among oncology patients and control subjects, according to diagnosis or to duration or type of chemotherapy. However significantly more oncology patients had atypical naevi (P < 0.05) and acral naevi (P < 0.0001) than controls. One patient developed a malignant melanoma 13 years after chemotherapy and radiotherapy for rhabdomyosarcoma. These findings support an association between treatment for childhood cancer and acral naevi and suggest that atypical naevi may also be associated with chemotherapy in childhood.
Green
A
A
Queensland Institute of Medical Research, University of Qld, Brisbane, Australia.
Smith
P
P
McWhirter
W
W
O'Regan
P
P
Battistutta
D
D
Yarker
M E
ME
Lape
K
K
D000293:Adolescent; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001315:Australia; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D008297:Male; D008545:Melanoma / Q000209:etiology*; D009369:Neoplasms / Q000150:complications; D009506:Nevus / Q000209:etiology*; D015996:Survival Rate; D013997:Time Factors
D000970:Antineoplastic Agents